FIG. 1.

Patient neoadjuvant immunotherapy disposition. For 18 patients with locally advanced melanoma, pretreatment biopsy was performed for immune-profiling and Tex frequency determination. One patient was excluded because of a pretreatment biopsy with an inadequate number of cells for analysis. The patients were stratified to a neoadjuvant immunotherapy group determined by their Tex frequency. The patients with Tex higher than 20% received PD-1 monotherapy, and those with Tex lower than 20% received anti-PD-1/CTLA-4 combination therapy. Three patients had neoadjuvant regimens not aligned with their Tex frequency due to patient preference or anticipated poor tolerance of the risk for immune-related adverse events (irAEs) with combination immunotherapy. Nine patients received neoadjuvant treatment with anti-PD-1 monotherapy. One patient received anti-PD-L1 monotherapy (grouped with anti-PD-1 for simplification), and seven patients received anti-PD-1/CTLA-4 combination therapy